Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

6.440 +0.320 (+5.23%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 30, 2021

Good morning, investor! We're starting off Tuesday with a breakdown of the biggest pre-market stock movers you need to know about!

Via InvestorPlace

50 Biggest Movers From Yesterday ↗

November 30, 2021

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial...

Via Benzinga

Adagio shares soar on antibody potential against new COVID variant omicron ↗

November 29, 2021

Stifel analyst Stephen Willey believes vaccines alone are unlikely to sufficiently address the COVID-19 pandemic.

Via Talk Markets

3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries ↗

November 29, 2021

The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a h...

Via Benzinga

Why Vir Biotechnology Is Up More Than 13% Today ↗

November 29, 2021

Investors are looking to capitalize on the latest curveball thrown by the coronavirus contagion.

Via The Motley Fool

33 Stocks Moving In Monday's Mid-Day Session ↗

November 29, 2021

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational...

Via Benzinga

Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail? ↗

November 29, 2021

Smaller companies are working on next-generation approaches to Covid treatment.

Via Investor's Business Daily

56 Biggest Movers From Friday ↗

November 29, 2021

Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on...

Via Benzinga

48 Stocks Moving In Friday's Mid-Day Session ↗

November 26, 2021

Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 26, 2021

Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 68.43% to $17.18 during Friday's pre-market session. The market value of their outstanding shares is at $119.6...

Via Benzinga

US Government Agrees To Purchase GSK-Vir Biotech's COVID-19 Antibody Doses Worth $1B ↗

November 17, 2021

The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 17, 2021

Gainers Rockwell Medical (NASDAQ:RMTI) shares rose 47.27% to $0.71 during Wednesday's pre-market session. The company's market cap stands at $66.5 million. The...

Via Benzinga

The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment ↗

November 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 17, 2021

Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

25 Stocks Moving in Wednesday's Pre-Market Session ↗

November 17, 2021

Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10...

Via Benzinga

GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19 ↗

November 12, 2021

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered...

Via Benzinga

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

3 Vaccine Stocks With Big Opportunities Outside of COVID-19 ↗

November 11, 2021

For most of the past two years, all the focus has been on the coronavirus, but these biotechs have big plans to develop inoculations against other diseases, too.

Via The Motley Fool

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Why Vir Biotechnology Stock Is Sliding Today ↗

November 05, 2021

Efficacy results for oral antivirals from Pfizer and Merck are weighing heavily on Vir today.

Via The Motley Fool

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

GlaxoSmithKline Drops Research On Otilimab In COVID-19 ↗

October 27, 2021

GlaxoSmithKline Plc (NYSE: GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2021 ↗

October 25, 2021

Upgrades According to Wedbush, the prior rating for Regions Financial Corp (NYSE:

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

October 25, 2021

Wells Fargo boosted Bank of America Corporation (NYSE:B...

Via Benzinga

GlaxoSmithKline: My Top Value Stock For The Week ↗

October 23, 2021

GSK, one of the biggest pharmaceuticals companies in the world, is seeing a lot of success with new drugs and plenty more in the pipeline. Better yet for would-be investors, the stock is still very...

Via Talk Markets

Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters ↗

October 22, 2021

The CDC authorized boosters from J&J, Moderna and a mix-and-match approach.

Via Investor's Business Daily

The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies ↗

October 15, 2021

Companies working on sorely needed Covid treatments are innovating to keep up.

Via Investor's Business Daily

AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial ↗

October 11, 2021

AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 06, 2021

Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

All News about Vir Biotechnology, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today